ライフサイエンスコーパス: thrombogenic

1 components, activates blood monocytes and is thrombogenic.

2 e to the design of future VADs that are less thrombogenic.

3 induced immunologically in these animals are thrombogenic.

4 n has been reported to be antiangiogenic and thrombogenic.

5 proteins retained their antigen binding and thrombogenic activities.

6 nction of A2 as a force sensor in regulating thrombogenic activity in the vasculature.

7 sence of blood factors that reflect enhanced thrombogenic activity would be associated with an increa

8 Very large VWF multimers have the greatest thrombogenic activity, which is attenuated by cleavage i

9 on into the potential role of fibulin-1 as a thrombogenic agent.

10 significant antitumor effect, however, these thrombogenic agents had to occlude medium and large vess

11 he phospholipid binding site of beta2GPI are thrombogenic and activate endothelial cells.

12 expected to result in reduced inhibition of thrombogenic and anti-inflammatory activity on the endot

13 mmunization with beta2GPI, and these Abs are thrombogenic and cause pregnancy loss in mice.

14 lotted-tube stainless steel stents were more thrombogenic and created more extensive vascular injury

15 ), may function as a homeostatic response to thrombogenic and hypertensive stimuli and may have parti

16 whether drug-eluting coatings are inherently thrombogenic and if the response to these materials was

17 Thrombogenic and inflammatory mediators, such as thrombi

18 We suggest that blood-borne TF is inherently thrombogenic and may be involved in thrombus propagation

19 The uremic milieu is profoundly thrombogenic and upregulates vSMC TF levels by increasin

20 he phospholipid-binding site of beta2GPI are thrombogenic and whether they activate endothelial cells

21 hrombi and thrombus-derived vasoconstrictor, thrombogenic, and inflammatory substances, however, redu

22 These include thrombin and thrombogenic arterial wall substrates such as tissue fac

23 Fourth, increasing appreciation of thrombogenic atrial substrate and the common coexistence

24 Third, emerging evidence indicates that a thrombogenic atrial substrate can lead to atrial thrombo

25 olymorphism and metabolic, inflammatory, and thrombogenic blood markers.

26 Baseline thrombogenic blood tests included 6 hemostatic variables

27 a transmembrane receptor that initiates the thrombogenic cascade by assembly with the serine proteas

28 tissue factor (TFt), to locally initiate the thrombogenic cascade.

29 or vascular endothelial cells that initiates thrombogenic cascades, which may play a role in determin

30 mediates prostaglandin E(2) potentiation of thrombogenic coagonists including collagen and adenosine

31 sis was induced by x-ray-guided placement of thrombogenic-coated, MR-lucent stents (n=5).

32 , 1a and 1b spontaneously self-assemble into thrombogenic collagen-mimetic materials because of hydro

33 le magnesium scaffold was significantly less thrombogenic compared with the Absorb bioresorbable vasc

34 Plaque rupture exposes thrombogenic components of the plaque, activating the cl

35 lformations will occur more frequently under thrombogenic conditions, such as those induced by thalid

36 In addition to the thrombogenic content of a plaque, also the hemodynamic m

37 covered by a fibrous cap that separates the thrombogenic core from the blood.

38 s, and provide a tool for the design of less thrombogenic devices.

39 rther evaluation as a possible treatment for thrombogenic disorders.

40 Demonstration of a thrombogenic effect of murine anti-cardiolipin antibodie

41 Treatment with IVIG inhibits the thrombogenic effects of aPL in vivo and reduces the leve

42 promotes inflammation, oxidative stress, and thrombogenic events.

43 sed diabetic and nondiabetic patients of the Thrombogenic Factors and Recurrent Coronary Events posti

44 es in blood lipids, insulin sensitivity, and thrombogenic factors.

45 Factors related to evolution of the thrombogenic fibrotic atrial cardiomyopathy support the

46 enabled the rapid immobilization of an anti-thrombogenic film in the presence of whole blood and per

47 eaves von Willebrand factor to smaller, less thrombogenic forms.

48 Willebrand factor multimers to generate less thrombogenic fragments.

49 or (VWF) in plasma to generate smaller, less thrombogenic fragments.

50 example, platelet deposition at the normally thrombogenic graft surface was substantially reduced rel

51 travitreal injection of Ocriplasmin (Jetrea, Thrombogenics Inc, USA, Alcon/Novartis EU).

52 h led to low omega6/omega3, atherogenic, and thrombogenic index.

53 The atherogenic and thrombogenic indexes (AI and TI, respectively) in soft m

54 eated and control mice, using a standardized thrombogenic injury procedure, and the area (size) of th

55 A standardized thrombogenic injury was subsequently induced in the femo

56 Plaque ruptures that expose larger areas of thrombogenic intramural debris to flowing blood in areas

57 In a mouse model with a relatively mild thrombogenic lesion, TF-dependent FVIII activation sets

58 lly have thin fibrous caps overlying a large thrombogenic lipid core rich in lipid-laden macrophages.

59 optosis, probably promotes formation of this thrombogenic lipid pool whose size correlates with plaqu

60 Lipoprotein(a) is an atherogenic and thrombogenic lipoprotein, and has been implicated in the

61 e anticoagulant annexin A5 shield could be a thrombogenic mechanism in the aPL syndrome.

62 a deleterious effect of diet on CVD risk via thrombogenic mechanisms.

63 fects of AF-related remodeling on the atrial thrombogenic milieu by using radiofrequency ablation (RF

64 atic pathway while attenuating the extrinsic thrombogenic pathway.

65 e proteases generated during inflammatory or thrombogenic pathways would elevate calcium concentratio

66 h, low-attenuating tissue layer that covered thrombogenic plaque components.

67 y which we have been able to investigate the thrombogenic potential of blood-borne TF.

68 mong standard mouse models, we evaluated the thrombogenic potential of platelets from healthy volunte

69 The thrombogenic potential of platelets subjected to mainstr

70 orphisms were suggested to contribute to the thrombogenic potential of S. sanguis.

71 To assess the thrombogenic potential of the genetically engineered smo

72 po(a) may have a comparatively higher athero-thrombogenic potential than parent Lp(a).

73 ructural remodeling did not predict post-RFA thrombogenic potential.

74 r are critical players in the control of the thrombogenic process.

75 panded and novel role for L1 in vascular and thrombogenic processes.

76 is the dominant contributor to its favorable thrombogenic profile.

77 Antiphospholipid antibodies (aPL) have thrombogenic properties in vivo, through their interacti

78 d polyclonal anticardiolipin antibodies have thrombogenic properties in vivo.

79 investigation to demonstrate the novel anti-thrombogenic properties of L-AME, when in solution and w

80 rkably, one of the monoclonal antibodies has thrombogenic properties when tested in an in vivo mouse

81 aterial for osseous reconstruction given its thrombogenic properties.

82 ite with a tumor delivery agent, this potent thrombogenic protein in its truncated form (tTF) can be

83 sion of plasminogen activator inhibitor-1, a thrombogenic protein.

84 gy is plaque rupture with exposure of highly thrombogenic, red cell-rich necrotic core material.

85 Furthermore, a delayed and markedly reduced thrombogenic response was still evident in VWF(-/-), GPV

86 stress and inflammation, and inhibiting the thrombogenic response.

87 ture susceptibility to both inflammatory and thrombogenic responses caused by hypercholesterolemia.

88 phocytes, contribute to the inflammatory and thrombogenic responses, brain injury, and neurological d

89 eraction of collagen with VWF and subsequent thrombogenic responses.

90 The potential thrombogenic risk of cyclooxygenase-2 inhibitors remains

91 hat although rapid atrial rates increase the thrombogenic risk, AF may further potentiate this risk.

92 The data are consistent with a thrombogenic role for S. sanguis in human disease, contr

93 There is increasing evidence regarding the thrombogenic role of neutrophils in essential thrombocyt

94 hirudin was assessed in vitro and in vivo on thrombogenic segments in chronically exteriorized femora

95 at doses that inhibited fibrin deposition on thrombogenic segments of arteriovenous shunts.

96 s forming on endovascular metallic stents or thrombogenic segments of vascular graft interposed in ex

97 tivity and most likely acts by pacifying the thrombogenic site of vascular injury.

98 ing in vascular shear flow and emigration at thrombogenic sites.

99 or expression may play a role in promoting a thrombogenic state in HITT.

100 e potential therapeutic role of TFPI in this thrombogenic state, mice were treated with intravascular

101 deposition in an animal model that combines thrombogenic stimulation with increased PAI-1 activity.

102 e molecular clock regulate the response to a thrombogenic stimulus in vivo.

103 mbin inhibitors is needed to "passivate" the thrombogenic substrate (disrupted arterial wall) and ach

104 aque rupture, smooth muscle cells may be the thrombogenic substrate.

105 (2 dynes/cm2) to simulate venous flow over a thrombogenic surface.

106 rich thrombus by tethering the platelet to a thrombogenic surface.

107 of P2Y(12) in mediating platelet adhesion to thrombogenic surfaces (collagen, von Willebrand factor)

108 Platelets bound to thrombogenic surfaces have been shown to support activat

109 The pS-NO-BSA coating of thrombogenic surfaces reduces platelet adhesion and aggr

110 ased rate of platelet aggregate formation on thrombogenic surfaces, leading to accelerated thrombus g

111 tiating the adhesion of flowing platelets to thrombogenic surfaces.

112 Increasing evidence suggests that the thrombogenic tendency in atrial fibrillation is related

113 Human lipid-rich plaques were more thrombogenic than less advanced atherosclerotic plaques.

114 strutted (162 mum) stents were 1.5-fold more thrombogenic than otherwise identical thin-strutted (81

115 We describe thrombogenic tissue factor (TF) on leukocyte-derived mic

116 triggers are known, our knowledge about the thrombogenic transcriptome changes in the microvessels i

117 The proteolysis converts hyper-reactive and thrombogenic ULVWF into smaller and less adhesive plasma

118 iplatelet activity when coated on a normally thrombogenic vascular graft situated in an arteriovenous

119 1 repeats, member 13) proteolysis of highly thrombogenic von Willebrand factor (VWF) multimers may a